| Systematic (IUPAC) name | |
|---|---|
| (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)- 3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Intravenous (to induce labor), intra-amniotic (to induce abortion) |
| Pharmacokinetic data | |
| Half-life | 3 to 6 hours in amniotic fluid, less than 1 minute in blood plasma |
| Identifiers | |
| CAS number | 551-11-1 38562-01-5 |
| ATC code | G02AD01 |
| PubChem | CID 5280363 |
| IUPHAR ligand | 1884 |
| DrugBank | DB01160 |
| ChemSpider | 4445570 |
| KEGG | D01352 |
| ChEMBL | CHEMBL815 |
| Chemical data | |
| Formula | C20H34O5 |
| Mol. mass | 354.48 g/mol |
|
|
| (what is this?) (verify) |
|
Prostaglandin F2α (PGF2α in prostanoid nomenclature) is pharmaceutically termed Dinoprost (INN) is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
In domestic mammals, it is produced by the uterus when stimulated by oxytocin, in the event that there has been no implantation during the follicular phase. It acts on the corpus luteum to cause luteolysis, forming a corpus albicans and stopping the production of progesterone. Action of PGF2α is dependent on the number of receptors on the corpus luteum membrane.
The PGF2α isoform 8-iso-PGF2α was found in significantly increased amounts in patients with endometriosis, thus being a potential causative link in endometriosis-associated oxidative stress.[1]
PGF2α acts by binding to the prostaglandin F2α receptor.it is also commercially available as (Enzaprost)
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||